ArticleFrontiers in oncology2025
Complete response of advanced HER2-amplified lung adenocarcinoma to cadonilimab combined with disitamab vedotin: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human epidermal growth factor receptor 2 (HER2) gene amplification in lung adenocarcinoma is associated with aggressive tumor behavior and poor prognosis. Currently, there is no standard targeted therapy for HER2-amplified lung cancer. Case summary: A 60-year-old male presented with a mass in the right cervical spine area. Imaging and pathological examinations confirmed stage IV (T4N3M1) lung adenocarcinoma with metastases to both lungs, multiple lymph nodes, the pleura, the left adrenal gland, and the meninges. Genetic testing revealed HER2 gene amplification and low programmed death-ligand 1 (PD-L1) expression (tumor proportion score <1%). The patient declined conventional chemotherapy due to concerns about side effects. With his informed consent, he was treated with a combination of cadonilimab (a PD-1/cytotoxic T-lymphocyte antigen 4 bispecific antibody) and disitamab vedotin (an anti-HER2 antibody-drug conjugate), administered intravenously every 3 weeks. After nine treatment cycles over 6 months, imaging assessments showed complete disappearance of the pulmonary lesions, and the achieved complete response (CR) persisted for at least 7 months. The treatment was well-tolerated, and the patient maintained an excellent performance status (Eastern Cooperative Oncology Group score of 0) without significant adverse effects. Conclusion: Treatment with cadonilimab and disitamab vedotin induced a sustained complete response in a patient with advanced HER2-amplified lung adenocarcinoma who declined chemotherapy. Thus, this combination therapy may offer a promising, effective, and well-tolerated treatment alternative for similar patients. Further clinical trials are warranted to validate these findings and potentially establish a new standard of care for this subset of lung cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.